The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer
Open accessAbstract
BACKGROUND: Long non-coding RNA (lncRNA) H19 has been well studied playing an important role in breast cancer (BC) progress and the expression of H19 may service as a diagnostic target for BC. However, it is unclear if circulating lncRNA H19 could as a potential biomarker for BC diagnosis and monitor. OBJECTIVE: The objective of our study was to determine whether plasma lncRNA H19 could be used as biomarkers for the screening and early diagnosis of breast cancer. METHODS: In this study, we carried out a quantitative real-time PCR (qRT-PCR) method to examine the expression levels of lncRNA H19 in 24 pairs of BC tissues and 20 pairs of BC plasma. The differentially expressed of plasma H19 was further validated in another 102 BC patients and 96 healthy controls. The potential correlations between plasma H19 levels and clinicopathological characteristics were analyzed. Receiver operating characteristic (ROC) curve was performed to evaluate the diagnostic values of plasma H19 between 30 early stage BC patients and 30 healthy controls. 24 paired pre- and postoperative plasma samples were detected to assess the tumor monitoring values. RESULTS: The results revealed that the expression of H19 was significantly increased in BC tissues and plasma compared with healthy controls (P< 0.05), and plasma H19 levels were significantly correlated with estrogen receptor (ER) (P= 0.008), progesterone receptor (PR) (P= 0.025), c-erbB-2 (P= 0.043) and lymph node metastasis (P= 0.006). The area under the ROC curve (AUC) of plasma H19 was 0.81(sensitivity, 56.7%; specificity, 86.7%; P< 0.0001), which was higher than the values of carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153). Furthermore, plasma H19 levels were significantly decreased in postoperative samples than preoperative samples (P= 0.0006). CONCLUSION: Plasma H19 may serve as a potential biomarker for BC early screening and prognosis monitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq526 · Cited by 691
Self-citationKogure, T., Yan, I. K., Lin, W.-L., & Patel, T. (2013) · Genes & Cancer · doi:10.1177/1947601913499020 · Cited by 303
Cited by
Long Non-Coding RNA in the Pathogenesis of Cancers
Chi, Y., Wang, D., Wang, J., Yu, W., & Yang, J. (2019) · Cells · doi:10.3390/cells8091015 · Cited by 791
Self-citationClinical utility of circulating non-coding RNAs — an update
Anfossi, S., Babayan, A., Pantel, K., & Calin, G. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0035-x · Cited by 450
H19 lncRNA: Roles in tumorigenesis
Ghafouri-Fard, S., Esmaeili, M., & Taheri, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109774 · Cited by 277
Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy
Qian, Y., Shi, L., & Luo, Z. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.612393 · Cited by 261
Self-citation
Metadata
- Authors
- Zhang, K., Luo, Z., Zhang, Y., Zhang, L., Wu, L., Liu, L., Yang, J., Song, X., & Liu, J.
- Venue
- Cancer Biomarkers
- Publisher
- SAGE Publications
- Published
- 2016-08-03
- Volume
- 17
- Issue
- 2
- Pages
- 187-194
- ISSN
- 1574-0153 (ISSN-L)
- 1875-8592
- OpenAlex
- W2468720336
- Cited by
- 199
- References
- 4
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.